Therapeutic drug monitoring of Meropenem, Linezolide and Tigecyclin in liver failure. Quantification of liver function with Maximal Liver Function Capacity test (LiMAx-Test).

Therapeutic drug monitoring of Meropenem, Linezolide and Tigecyclin in liver failure. Quantification of liver function with Maximal Liver Function Capacity test (LiMAx-Test). - LiMeS-study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00008888

Enrollment

420

Registered

2015-07-17

Start date

2014-03-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K72.0

Interventions

Group 1: Measurement of liver function with LiMAx test (Maximal Liver Function Capacity Test) and therapeutic drug Monitoring (Serum, Urine, Dialysat) in critically ill patients with assumed liver dys

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Existence of liver failure and indication of therapy with Meropenem, Linezolide or Tigecycline 2. Age >1818<90 3. Existing inform consent (patient or legal caregiver)

Exclusion criteria

Exclusion criteria: 1. Allergy against Methacetin 2. Age 90 3. Pregnancy, breast feeding 3. Missing inform consent 4. patient cannot cooperate during study due to mental disturbance

Design outcomes

Primary

Measure	Time frame
Correlation between quantitative liver function measured by LiMAx-test and Serum-Drug-Level (Meropenem, Linezolide or Tigecycline) after maintaining a constant drug Level (>36h after beginning of antibiotic therapy)	—

Secondary

Measure	Time frame
Improvement of dosage of hepatic metabilised antibiotics in liver failure	—

Countries

Germany

Contacts

Public ContactMagnus Kaffarnik

Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

magnus.kaffarnik@charite.de030450652235

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 26, 2026